ORBIMED ADVISORS LLC

About ORBIMED ADVISORS LLC

ORBIMED ADVISORS LLC is a life-sciences-focused investment firm with a strong footprint in the governance of U.S.-listed biotechnology companies. Across the affiliated companies you listed—89bio, Janux Therapeutics, Corvus Pharmaceuticals, Adicet Bio, and Repare Therapeutics—OrbiMed typically participates through its investment professionals and board representatives rather than through a single operating executive. Public-company filings show OrbiMed partners serving in director roles at multiple portfolio companies, including Peter A. Thompson, M.D. at Janux Therapeutics and Corvus Pharmaceuticals, and Carl L. Gordon, Ph.D. at Adicet Bio, where he serves as board chair. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1710072/000155837024005905/tmb-20240607xdef14a.htm)) For SEO and corporate-governance purposes, the most notable current or recent role to associate with OrbiMed Advisors LLC is therefore Board Member, or more precisely an institutional investor representative on the boards of portfolio companies. In that capacity, OrbiMed is known for supporting governance, financing, and strategic oversight for development-stage and commercial-stage healthcare businesses. The company’s representatives bring deep experience in biotechnology investing, molecular biology, drug development, and healthcare private equity, and that expertise is frequently cited in public filings as a qualification for board service. This makes OrbiMed a meaningful governance stakeholder in public biotech markets, particularly on the NASDAQ and NYSE. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1710072/000155837024005905/tmb-20240607xdef14a.htm)) OrbiMed’s broader profile is that of a global healthcare investment manager with more than 20 years of experience investing across biopharmaceuticals, medical devices, diagnostics, and healthcare services. Its board-level influence is typically exercised through experienced partners who help guide capital allocation, clinical-development priorities, portfolio strategy, and value-creation decisions. Public disclosures show that its affiliated directors have served on numerous boards and have often been involved in companies pursuing major strategic milestones, including financing rounds, pipeline progression, and other board-approved corporate actions. In short, OrbiMed Advisors LLC is best characterized as an influential healthcare investor and governance participant rather than an operating company executive, with a particularly notable presence in U.S. public biotech governance. ([orbimed.com](https://www.orbimed.com/about/?utm_source=openai))